By Ashby Jones
Oh, if were given a nickel, or a penny, or even one tenth of one penny, for every dollar coughed up by the pharmaceutical industry in fines for improper drug marketing, we’d be blogging poolside from the roof our our own Caribbean hotel while these guys played live behind us, over and over, day after day.
And were that the case, we’d quite possibly get a lot richer very soon.
Turns out, federal prosecutors are seeking roughly $1 billion to resolve a long-running probe into Johnson & Johnson’s marketing of the antipsychotic drug Riseprdal. That’s right, $1 billion. Click here for the WSJ story.
Since 2004, the federal government has been investigating whether J&J’s Janssen Pharmaceutica unit improperly promoted Risperdal for unapproved uses, J&J has said in filings with the Securities and Exchange Commission.
In its latest filing Tuesday, the New Brunswick, N.J., company said it had set aside an unspecified sum to settle potential civil and criminal charges.
J&J said its discussions with the government “are ongoing and it is inappropriate to speculate.” Spokespeople for federal prosecutors in Philadelphia and Washington, D.C., said they don’t comment on such matters.
A settlement of around $1 billion would be among the industry’s largest, and likely have a material impact on J&J’s quarterly financial results. Prosecutors are pushing J&J to reach a settlement soon, said a person familiar with the situation.
Officials at J&J were surprised at the size of the sum that prosecutors are seeking, according to the people familiar with the matter.
Prosecutors have been citing as a benchmark a $1.4 billion settlement that Eli Lilly & Co. reached in 2009 to resolve a probe into alleged improper marketing of its antipsychotic drug Zyprexa, according to one of the people.
Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk
Saturday, May 14, 2011
Feds Seeking $1B From J&J Over Risperdal Marketing - Law Blog - WSJ
via blogs.wsj.com
Subscribe to:
Post Comments (Atom)
1 comment:
Eli Lilly Zyprexa Claims Still Unresolved
Eli Lilly Zyprexa can cause diabetes I took Zyprexa a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
This is a powerful drug that can damage a young person physiologically for life. Please take with caution and learn as much as you can about side effects. Eli Lilly's #1 cash cow Zyprexa drug sale $40 billion dollars so far,has a ten times greater risk of causing type 2 diabetes over the non-user of Zyprexa. So,here we have a conflict of interest that this same company also is a big profiteer of diabetes treatment.
FIVE at FIVE
The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold for "children in foster care, people who have trouble sleeping, elderly in nursing homes."
Five at Five was the Zyprexa sales rep slogan, meaning 5mg dispensed at 5pm would keep patients quiet.
Google * Eli Lilly Zyprexa * and read the links. I took Zyprexa it gave me diabetes and was as addictive as tobacco.How so? Because withdrawal is accompanied by severe insomnia for 6 weeks.
-- Daniel Haszard Zyprexa Whistle-blower
Post a Comment